



SUPPLEMENTARY FIGURE: OVERALL SURVIVAL OF PATIENTS WHO ACHIEVED CR/PR TO RUXOLITINIB VERSUS NON-RESPONDERS [EXCLUDING PATIENTS WHO DIED BEFORE DAY 28](LFU = last follow up; Blue = non-responders; Green – Patients achieving CR/PR; X axis shows time in days)

SUPPLEMENTARY TABLE

LOGISTIC REGRESSION ANALYSIS FOR PREDICTORS OF RESPONSE TO RUXOLITINIB

VARIABLE	RISK	95% CI	p VALUE
Indication for transplant – Malignant Non-malignant	1.9 Reference	0.564 – 6.410	0.30
Number of organs involved	1.051	0.489 – 2.257	0.899
Grade of Acute GVHD II III IV	Reference 0.5 0.405	 0.013 – 19.562 0.034 – 4.854	 0.711 0.475
Donor Type MSD/MRD MUD Haplo	Reference 4.333 1.284	 0.386 – 48.610 0.358 – 4.602	 0.235 0.701

MANN-WHITNEY TEST COMPARING RESPONDERS TO RUXOLITINIB VERSUS NON-RESPONDERS

VARIABLE	p VALUE
Number of days of steroid therapy prior to initiation of Ruxolitinib	0.689